D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is discontinuing the development of CT-0525 as part of a “strategic reprioritization. The firm reduced HERII cancers from its projections.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CARM:
- Carisma Therapeutics announces restructuring, 34% workforce reduction
- Carisma Therapeutics Restructures Amid Strategic Refocus
- Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
